Pipeline
R&D
Careers
Contact
Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192
Product |
Therapeutic Area |
Pre-Clinical |
Phase 1 |
Phase 2 |
Phase 3 |
| Daclizumab | Multiple Sclerosis |  |
|
|
|
| Elotuzumab (HuLuc63) | Multiple Myeloma | |
|
|
|
| TRU-016 | Chronic Lymphocytic Leukemia | |
|
||
| Non-Hodgkin’s Lymphoma | |
||||
| AIID | |
||||
| Volociximab (M200) | Lung Cancer | |
|
||
| PDL192 | Solid Tumors | |
|
Learn More about our R&D approach..
More »
Recent Publications
Press Releases